Selected phase 1/2 trials of autologous CD19-targeted CAR T cells for patients with R/R NHL
| Reference . | No. of patients treated . | CAR construct . | CAR T-cell dose or dose range . | ORR, %/CR rate, % . |
|---|---|---|---|---|
| 21 | DLBCL (13), TFL (4), FL (2), PMBL (2), MCL (1) | CD19scFv/CD28/CD3ζ | 1 × 106/kg to 6 × 106/kg | 73/55 |
| 41 | DLBCL (2), TFL (2), PCNSL (1) | CD19scFv/CD28/CD3ζ and CD19scFv/CD3ζ | 2 × 107/m2 to 2 ×108/m2 | 0/0 |
| 42 | DLBCL (11), TFL (10), FL (5), MCL (4) | CD19scFv/4-1BB/CD3ζ | 2 × 105/kg to 2 × 107/kg (CD4:CD8, 1:1) | 63/33 |
| 43 | DLBCL (14), FL (14) | CD19scFv/4-1BB/CD3ζ | 2 × 105/kg to 2 × 107/kg | 64/57 |
| 10 | DLBCL (77), PMBCL (8), TFL (16) | CD19scFv/CD28/CD3ζ | 2 × 106/kg | 82/54 |
| Reference . | No. of patients treated . | CAR construct . | CAR T-cell dose or dose range . | ORR, %/CR rate, % . |
|---|---|---|---|---|
| 21 | DLBCL (13), TFL (4), FL (2), PMBL (2), MCL (1) | CD19scFv/CD28/CD3ζ | 1 × 106/kg to 6 × 106/kg | 73/55 |
| 41 | DLBCL (2), TFL (2), PCNSL (1) | CD19scFv/CD28/CD3ζ and CD19scFv/CD3ζ | 2 × 107/m2 to 2 ×108/m2 | 0/0 |
| 42 | DLBCL (11), TFL (10), FL (5), MCL (4) | CD19scFv/4-1BB/CD3ζ | 2 × 105/kg to 2 × 107/kg (CD4:CD8, 1:1) | 63/33 |
| 43 | DLBCL (14), FL (14) | CD19scFv/4-1BB/CD3ζ | 2 × 105/kg to 2 × 107/kg | 64/57 |
| 10 | DLBCL (77), PMBCL (8), TFL (16) | CD19scFv/CD28/CD3ζ | 2 × 106/kg | 82/54 |
DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; MCL, mantle cell lymphoma; ORR, overall response rate; PCNSL, primary central nervous system lymphoma; PMBL, primary mediastinal B-cell lymphoma; TFL – transformed follicular lymphoma.